Simultaneous Engagement of Networks for Alleviating Pain (SENAP)

Starting soon · Phase 1

Conditions studied: Neuropathic Pain, Postherpetic Neuralgia

In brief

This trial is investigating the acceptability and efficacy of PFM-guided cortical stimulation for the treatment of central neuropathic pain.

Key facts

Study ID

NCT07057206

Run by

University of Minnesota

People needed

20

Starts

2026-11-01

Expected to finish

2030-12-01

Last updated by the study team

2026-07-23

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 22 years
• Clinical diagnosis of a refractory chronic neuropathic pain syndrome suggestive of deafferentation or central pain. Non-limiting examples of these syndromes are:
• post-traumatic pain syndromes (e.g. plexopathies, radiation-induced injury)
• postsurgical pain syndromes (e.g. phantom limb pain, anesthesia dolorosa)
• postherpetic neuralgia
• Central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)
• Greater than 6 months of chronic neuropathic pain
• Average pain intensity over the past 30 days reported as 6 or greater on a 0-10 numeric rating scale (NRS)
• Multidisciplinary pain consensus review that establishes
• Pain is refractory to medical management
• Pain that is refractory to or unlikely to be altered by less invasive treatment and
• Pain distribution either does not permit attempts at relief by a targeted nerve block (e.g., post-stroke pain) or such blocks have provided <25% relief.
• Medication doses currently stable (no active titration or drug trials in progress) in the 30 days prior to baseline (immediately pre-surgical) study visit
• Ability to speak / read English
• Capable of understanding and providing informed consent (verified if necessary by a standard tool such as the MacArthur Competency Assessment)
• Women of childbearing age must be on regular use of an accepted contraceptive method(s).

You may not qualify if…

• Pregnancy, breastfeeding, or unwilling to maintain regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study if study procedures may cause risk to the fetus. Patients who become pregnant prior to the surgical implantation will be excluded from the study.
• Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI.
• Untreated or uncontrolled psychiatric illness (schizophrenia, bipolar disorder, obsessive-compulsive disorder), or personality disorders (e.g. borderline personality disorder) or other neuropsychiatric conditions that the evaluating clinician would recommend exclusion of the patient after neuropsychiatric evaluation.
• History of seizure disorder and seizure within the last year. Participants with a remote history of epilepsy will need documentation from their neurologist for eligibility.
• Suicide attempt within 12 months from baseline visit or imminent suicide risk in the judgment of study clinicians.
• Modified Scale for Suicidal Ideation Score of greater than or equal to 21
• History of diagnosed substance use disorder in the past 3 years. Benzodiazepines and/or opioids prescribed by a physician with use as directed do not count for this criterion. Cannabis/cannabinoid products will not be considered an exclusion if used under the auspices of a state-sponsored medical cannabis program.
• Major medical comorbidities increasing the risk of surgery including uncontrolled hypertension, severe diabetes, major organ system failure, need for chronic anticoagulation other than aspirin, active infection, immunocompromised state, or malignancy with < 5 years life expectancy.
• Inability to temporarily stop anticoagulation therapy (approximately 3 weeks total) for surgery and after surgery. Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation / antiaggregation therapy discontinuation.
• MRI (done within one year of the baseline period) with significant abnormalities other than those associated with the neurological disorder causing chronic pain.
• Implantable hardware not compatible with MRI or with the study or former metal worker that may pose risk from MRI.
• Previous ablative intracranial surgery for the management of a central pain syndrome.
• history of other neurosurgical procedures that may interfere with functioning of the device
• Active, pending, or planned litigation or workman's compensation claim related to the pain/injury. Current receipt of disability benefits, without a dispute or litigation, is not an exclusion.
• Requires ongoing or expected diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition
• Allergies or known hypersensitivity to materials in the implanted system (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel).
• Any other condition that, in the judgment of the PI or the Data Safety \& Monitoring Board, significantly increases risk of receiving an implanted neurostimulator.
• Those who require ongoing monitoring of a disease state by MRI.
• Inability to target the somatocognitive action network or cingulate opercular network on fMRI

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.